1. ESHO
congress 04-06 October 2026 in Erlangen – program available, registration open
The program for the 37th Annual Meeting of the ESHO (European
Society for Hyperthermic Oncology) from 04th – 6th of
October 2026 in Erlangen is now available: https://esho-congress.eu/
An exciting program
awaits you, covering topics such as clinical experiences and studies of
superficial and deep hyperthermia, immunology, and quality assurance.
Thermography-controlled
wIRA superficial hyperthermia used as a radiosensitizer will explicitly be
addressed in the "Focused Workshop: Re-irradiation and hyperthermia in
breast cancer" and in "Session 6: Clinical trials" (A. Kong presents
a planned study at Guy's Cancer Center / King's College London, A. Luechtenborg
presents first results of the HISTOTHERM study at the University Medical Center
Freiburg). In addition, wIRA-HT will be the subject of six posters.
Register now and visit us at the
industrial exhibition!
2. Extensive
skin metastases of ovarian cancer treated with combined superficial
hyperthermia and radiotherapy
An interesting case report from University Medical
Center Freiburg, Dept. of Radiation Oncology, was published in Strahlenther
Onkol. - https://pubmed.ncbi.nlm.nih.gov/42126534/.
The authors conclude: “Radiotherapy
combined with mild hyperthermia in addition to systemic treatment allows for
tumor control in the treated area, even with a reduced total radiation dose. To
the best of our knowledge, this is the first report of a long-term tumor-free
situation in the treatment area of skin metastases of ovarian cancer. This
novel treatment might also be beneficial for skin metastases from other
malignancies.”
A patient presenting with extensive high-grade cutaneous
metastases of ovarian cancer was successfully treated with a combination of
thermography-controlled wIRA superficial hyperthermia (39-43 °C) immediately
followed by low-dose hypofractionated radiotherapy and parallel systemic
treatment with carboplatin/gemcitabine. The patient responded well and remained
tumor free in the treatment area for more than 1 year.
3. Innovative
multimodal treatment of Stage IV invasive ductal carcinoma by metabolically
supported chemotherapy including hyperthermia
AK Slocum et al. from ChemoThermia Oncology Center in Istanbul /
Turkey published in Front Oncol an interesting case report on the successful
multi-modular treatment for a patient presenting with Stage IV invasive ductal
carcinoma with extensive osseous and lymph node metastases, poor performance
status and severe, debilitating pain.
OPEN ACCESS https://pmc.ncbi.nlm.nih.gov/articles/PMC13143783/
The protocol was based on Metabolically Supported
Chemotherapy (MSCT) consisting of docetaxel, doxorubicin, and cyclophosphamide
administered following a 14-hour fast and low dose insulin-induced mild
hypoglycemia, alongside a strict ketogenic diet, and included locoregional and
fever-range whole-body hyperthermia (using heckel-HT3000) as adjunctive
therapies.
※본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터를 전달받아 게시한 것임을 알립니다.
